These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7689447)

  • 21. [In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].
    Soussy CJ; Cluzel M; Derlot E; Exmelin L; Kitzis MD; Dabernat H; Le Noc P; Muller-Serieys C; Reverdy ME; Scheftel JM; Thabaut A
    Pathol Biol (Paris); 1996 Apr; 44(4):241-8. PubMed ID: 8763585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms underlying resistance of the bacteria responsible for nosocomial infections].
    Mainardi JL; Gutmann L
    Pathol Biol (Paris); 1998 Apr; 46(4):253-60. PubMed ID: 9769905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities.
    Wisplinghoff H; Seifert H; Tallent SM; Bischoff T; Wenzel RP; Edmond MB
    Pediatr Infect Dis J; 2003 Aug; 22(8):686-91. PubMed ID: 12913767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone use and fluoroquinolone resistance: is there an association?
    Richard P; Delangle MH; Merrien D; Barillé S; Reynaud A; Minozzi C; Richet H
    Clin Infect Dis; 1994 Jul; 19(1):54-9. PubMed ID: 7948558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in the distribution and antimicrobial susceptibility of causative pathogens of device-associated infection in Korean intensive care units from 2006 to 2013: results from the Korean Nosocomial Infections Surveillance System (KONIS).
    Choi JY; Kwak YG; Yoo H; Lee SO; Kim HB; Han SH; Choi HJ; Kim HY; Kim SR; Kim TH; Lee H; Chun HK; Kim JS; Eun BW; Kim DW; Koo HS; Cho EH; Lee K;
    J Hosp Infect; 2016 Apr; 92(4):363-71. PubMed ID: 26876746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and treatment of community-acquired and hospital-acquired pneumonia.
    Foster MT
    Pharmacotherapy; 1993; 13(2 Pt 2):45S-50S. PubMed ID: 8474938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance patterns to beta-lactams and quinolones in clinical isolates of bacteria from Cuban hospitals.
    Gonzáles I; Niebla A; Vallin C
    Int J Clin Pharmacol Res; 1995; 15(1):17-22. PubMed ID: 7490170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
    Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S
    Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic resistance patterns of Gram-negative and Gram-positive strains isolated from inpatients with nosocomial infections in a tertiary hospital in Beijing, China from 2011 to 2014.
    Zhu X; Tong A; Wang D; Sun H; Chen L; Dong M
    J Chemother; 2017 Oct; 29(5):317-320. PubMed ID: 27347770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What have we learnt from community-acquired infections in Hong Kong?
    Ling JM; Lam AW; Chan EW; Cheng AF
    J Antimicrob Chemother; 2003 Apr; 51(4):895-904. PubMed ID: 12654732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
    Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
    Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surveillance on drug resistance of gram-negative bacilli isolated from hospital acquired infections and community acquired infections (2000 - 2001)].
    Li JT; Li Y; Wang J;
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1035-45. PubMed ID: 12899774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic resistance among nosocomial isolates in a Croatian intensive care unit--results of a twelve-year focal surveillance of nosocomial infections.
    Barsic B; Tambic A; Santini M; Klinar I; Kutlesa M; Krajinovic V
    J Chemother; 2004 Jun; 16(3):273-81. PubMed ID: 15330325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
    Nseir S; Ader F; Marquette CH; Durocher A
    Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.